SCHEMBL973371

SCHEMBL973371

CC(=O)Nc1c[c]c(O)cc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 5/20 0.55
MEN1 O00255 3/20 0.55
MAPT P10636 3/20 0.55
ALDH1A1 P00352 3/20 0.55
CA12 O43570 1/20 0.55
BRD4 O60885 1/20 0.55
NR1I2 O75469 1/20 0.55
CA1 P00915 1/20 0.55
CA2 P00918 1/20 0.55
MB P02144 1/20 0.55
CYP1A1 P04798 1/20 0.55
CA3 P07451 1/20 0.55
CYP3A4 P08684 1/20 0.55
RARG P13631 1/20 0.55
TSHR P16473 1/20 0.55
ALOX5AP P20292 1/20 0.55
CA4 P22748 1/20 0.55
CA7 P43166 1/20 0.55
NR1I3 Q14994 1/20 0.55
CA9 Q16790 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1740872 0.80 TDP1 (0.55) KMT2AMEN1MAPTALDH1A1CA12
SCHEMBL1302981 0.80 PEPD (0.55) KMT2AMEN1MAPTALDH1A1CA1
SCHEMBL3064656 0.78 SMN1; SMN2 (0.50) KMT2AMEN1MAPTALDH1A1CA12
SCHEMBL2683899 0.78 SMN1; SMN2 (0.50) KMT2AMEN1MAPTALDH1A1CA12
SCHEMBL27544478 0.78 SMN1; SMN2 (0.50) KMT2AMEN1MAPTALDH1A1CA12
SCHEMBL95120 0.78 SMN1; SMN2 (0.50) KMT2AMEN1MAPTALDH1A1CA12
SCHEMBL6945609 0.77 TP53 (0.59) KMT2AMEN1MAPTALDH1A1CA12
SCHEMBL97146 0.76 SMN1; SMN2 (0.52) KMT2AMEN1MAPTALDH1A1CA12
SCHEMBL11220581 0.75 CYP17A1 (0.45) ALDH1A1CA12CA1CA9NAMPT
SCHEMBL861674 0.75 SMN1; SMN2 (0.84) KMT2AMEN1MAPTALDH1A1CA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-105358611-B The method for manufacturing non-roasting type electrode E.I.内穆尔杜邦公司 2018-07-17 CN claimed
EP-1765816-B1 SUBSTITUTED 1-PROPIOLYLPIPERAZINES HAVING AN AFFINITY FOR THE MGLUR5 RECEPTOR IN ORDER TO TREAT PAINFUL CONDITIONS GRUENENTHAL GMBH (DE) 2010-03-10 EP claimed
US-7300939-B2 Substituted 1-propiolylpiperazine compounds, their preparation and use GRUENENTHAL GMBH (DE) 2007-11-27 US claimed
US-20070112011-A1 Substituted 1-propiolylpiperazine compounds, their preparation and use GRUENENTHAL GMBH (DE) 2007-05-17 US claimed
EP-0996443-A1 CERTAIN DIARYLIMIDAZOLE DERIVATIVES; A NEW CLASS OF NPY SPECIFIC LIGANDS NEUROGEN CORPORATION (US) 2000-05-03 EP claimed
WO-1999001128-A1 CERTAIN DIARYLIMIDAZOLE DERIVATIVES; A NEW CLASS OF NPY SPECIFIC LIGANDS NEUROGEN CORPORATION (US) 1999-01-14 WO claimed
EP-4382546-A1 POLY(UREA-URETHANE) POLYMER BASF SE (DE) 2024-06-12 EP disclosed
WO-2024105029-A1 RECYCLABLE POLY(UREA-URETHANE) POLYMER AND COMPOSITE WITH DYNAMIC HINDERED UREA BONDS (HUBS) BASF SE (DE) 2024-05-23 WO disclosed
WO-2024105027-A1 CLOSED LOOP RECYCLING CONCEPT FOR COMPOSITES COMPRISING COVALENT ADAPTABLE POLY(UREA-URETHANE) NETWORKS WITH DYNAMIC HINDERED UREA BONDS BASF SE (DE) 2024-05-23 WO disclosed
EP-4305085-A1 POLYUREA COPOLYMER BASF SE (DE) 2024-01-17 EP disclosed
CN-116964122-A Polyurea copolymers 巴斯夫欧洲公司 2023-10-27 CN disclosed
CN-116916755-A Materials and methods for extending the shelf life of food products JP实验室公司 2023-10-20 CN disclosed
CN-113135922-B Azepane [4,3,2-cd ] isoindol-2-one derivatives and application thereof 中国药科大学 2023-05-30 CN disclosed
EP-1238975-A1 DIFLUOROMETHYLTRIAZOLONE COMPOUNDS, USE OF THE SAME AND INTERMEDIATES FOR THE PRODUCTION THEREOF Sumitomo Chemical Company, Limited (JP) 2002-09-11 EP disclosed
WO-2001051470-A1 PHENANTHRIDINE-N-OXIDES BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) 2001-07-19 WO disclosed
US-6121260-A Method of treating conditions susceptible to modulation of NPY receptors with diarylimidazole derivatives NEUROGEN CORPORATION (US) 2000-09-19 US disclosed
EP-0996443-A1 CERTAIN DIARYLIMIDAZOLE DERIVATIVES; A NEW CLASS OF NPY SPECIFIC LIGANDS NEUROGEN CORPORATION (US) 2000-05-03 EP disclosed
WO-1999001128-A1 CERTAIN DIARYLIMIDAZOLE DERIVATIVES; A NEW CLASS OF NPY SPECIFIC LIGANDS NEUROGEN CORPORATION (US) 1999-01-14 WO disclosed
US-5837649-A STORAGE STABILITY, NONBLEEDING, COLORFASTNESS; RECEPTIVE LAYER CONTAINS METAL COORDINATION COMPOUND; DIFFUSIBLE DYE CAPABLE OF FORMING CHELATE DAI NIPPON PRINTING CO., LTD. (JP) 1998-11-17 US disclosed
US-4006128-A CELLULOSE ACETATES, VINYL POLYMERS, POLYOLEFINS, POLYESTERS BAYER AKTIENGESELLSCHAFT (DT) 1977-02-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070112011-A1 Substituted 1-propiolylpiperazine compounds, their preparation and use GRM5, GRIK5, GRM1 KMT2A 3522/4885MEN1 4228/4885MAPT 3334/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.